Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Supernus Pharmaceuticals, Inc. Common Stock Intraday Chart
|Intraday||Last 52 Weeks|
|High||$ 17.49||$ 23.3008|
|Low||$ 16.82||$ 9.5101|
The current last sale of $17.17 is 80.54% Higher thanthe 52 week low.
Company Description (as filed with the SEC)
We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. In 2013, we launched Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), our two novel treatments for patients with epilepsy. In addition, we are developing multiple product candidates in psychiatry to address significant unmet medical needs and market opportunities for the treatment of Impulsive Aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). With SPN-810, we are initially developing the product to treat IA in patients who have ADHD. There are currently no approved products indicated for the treatment of IA. We subsequently plan to develop SPN-810 for treatment of IA in other CNS diseases, such as autism, bipolar disorder, schizophrenia, and some forms of dementia. ... More ...
Where does SUPN fit in the risk graph?
Nasdaq Official Price
|Annual EPS Est:||$0.31|
|Quarterly EPS Est:||0.08|